The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The impact of RBPs in the development of hematological malignancies and bone marrow failure
Miguel Gallardo, PhD, Spanish National Cancer Research Center (CNIO), Madrid, Spain, discusses the impact of RNA binding proteins (RBPs) in the development and progression of various hematological malignancies. Dr Gallardo first highlights how the over-expression of RBPs, including hnRNP K, can promote hematopoietic stem cell exhaustion and bone marrow failure, and then goes on to discuss some ongoing research in the field. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
